Inhalable mRNA vaccines for respiratory diseases: a roadmap

Area of Science:

• Vaccinology
• Pulmonary Drug Delivery
• Biotechnology

Background:

• Messenger RNA (mRNA) vaccines have revolutionized disease prevention, demonstrating high efficacy.
• Current mRNA vaccines face challenges in immune persistence and formulation stability for respiratory diseases.
• Inhaled mRNA vaccines present an opportunity for enhanced, localized, and long-lasting immune responses.

Purpose of the Study:

• To explore the potential of next-generation inhaled mRNA vaccines for respiratory diseases.
• To identify and address key challenges in the development of pulmonary mRNA delivery systems.
• To highlight recent advancements in overcoming translational hurdles for inhaled mRNA vaccines.

Main Methods:

• Review of recent advances in pulmonary delivery technologies for mRNA vaccines.
• Analysis of strategies for designing aerosol-stable and lung-stable mRNA formulations.
• Examination of methods for navigating pulmonary biological barriers.
• Discussion of progress in predictive modeling and measurement techniques for inhaled vaccines.

Main Results:

• Pulmonary delivery technologies show promise for overcoming formulation and stability issues.
• Strategies are emerging to enhance the stability and delivery of mRNA in the lungs.
• Progress is being made in understanding and overcoming biological barriers in the pulmonary system.
• Development of improved models and techniques is crucial for translation.

Conclusions:

• Inhaled mRNA vaccines offer a promising strategy for durable, tissue-specific respiratory immunity.
• Advances in formulation, delivery, and modeling are paving the way for successful translation.
• Overcoming pulmonary biological barriers and ensuring formulation stability are key to realizing the potential of inhaled mRNA vaccines.